Perimenopause & Menopause Guide: Symptoms & Options
The menopause transition can affect periods, temperature comfort, sleep and intimacy. Start with the symptoms affecting your life, then compare suitable choices with a clinician.
A clear next step
- Name the change or care question.
- Check whether help is urgent.
- Bring your history and priorities.
- Agree the next action and review.
Part of the Women’s Health research series.
On this page: choose your question
- The short answer
- Describe the transition in context
- Match the option to the symptom
- Discuss benefits, suitability and monitoring
- What changed in the FDA warnings?
- Compare supplement claims with the actual outcome
- Bleeding and follow-up still matter
- Your menopause treatment conversation
- Frequently asked questions
- Sources and editorial method
The short answer
Care can be tailored to the symptom, health history and preference. Hormone therapy can help selected symptoms, but the route, formulation and individual risk matter. Current warning changes should be explained accurately without describing treatment as risk-free. [1] [2]
Educational information for adults, primarily in a US care context. Use a qualified clinician for diagnosis and treatment. Do not change prescribed medicines from this guide. Guidance may differ by location, history and organs present.
Describe the transition in context
Bring the dates and pattern of your periods, symptoms, contraception and any surgery or medicines affecting bleeding. NICHD describes perimenopause as the transition before menopause, with symptoms that can include hot flashes, vaginal dryness and sleep changes. Not every midlife symptom should automatically be assigned to menopause. [1]
Ask whether the history is typical or whether another concern needs investigation. Keep fatigue, persistent pain or new bleeding in the discussion even when hot flashes are also present. Symptoms occurring together may need more than one care pathway.
Match the option to the symptom
| Concern | Discussion to have |
|---|---|
| Hot flashes/night sweats | Suitability of hormone or nonhormone prescription options and practical comfort measures. |
| Vaginal dryness or painful sex | Moisturizers, lubricants and whether local prescription treatment fits. |
| Sleep or mood changes | The sleep pattern, mental-health context and other possible contributors. |
| Bone health | Fracture risk and whether screening or treatment is indicated. |
A vaginal treatment and whole-body hormone treatment have different purposes. Ask what the proposed product is expected to help and what it will not address. Dryness does not require accepting painful sex as inevitable. [3]
Discuss benefits, suitability and monitoring
The Office on Women’s Health says benefits are more likely to outweigh risks when therapy starts before 60 or within ten years of menopause, while emphasizing personal suitability. Unexplained bleeding, relevant cancer, liver or clotting history can change options. Hormone therapy should not be started simply to prevent heart disease or with a promise to prevent dementia. [2]
Bring your complete history and ask whether the uterus is present, whether endometrial protection is needed, how the route affects the choice, and who reviews bleeding or other adverse effects. Do not copy someone else’s gel, patch or dose.
What changed in the FDA warnings?
In February 2026 the FDA approved labeling changes for six menopausal hormone-therapy products, removing specified cardiovascular, breast-cancer and probable-dementia statements from the boxed warning. That regulatory action does not mean all products became interchangeable or all risks disappeared. The current OWH explanation notes that other labeling still describes relevant risks and that the endometrial-cancer boxed warning remains on systemic estrogen-only products. [4] [2]
Ask the prescriber or pharmacist to explain the current label for the actual product being offered. A headline about warnings cannot decide whether a treatment fits you.
Compare supplement claims with the actual outcome
NCCIH finds that supplements and phytoestrogens have not clearly established consistent relief of menopausal symptoms, with formulation and safety uncertainties. “Plant-based” or “bioidentical” wording alone does not establish a safer or more effective option. [5]
If you want to try a complementary approach, bring the label and agree what benefit you would monitor. Keep prescribed care and the review date clear. The nutrition and supplements guide separates nutritional needs from symptom-treatment claims.
Bleeding and follow-up still matter
Bleeding after menopause should be checked, even if light or only once. Several causes are possible; it is not a cancer diagnosis, and it should not be dismissed as ordinary aging. Tell the clinician about hormone therapy and when it started. [6]
A good review asks whether the symptom that prompted treatment improved, whether adverse effects occurred, and whether your goals or history changed. Keep the plan flexible rather than treating the first prescription as a permanent decision.
Your menopause treatment conversation
Copy these prompts into a private note and bring them to your appointment. This original planning aid is not a validated score or diagnostic test.
- Top two symptoms and daily impact: write your note and one question.
- Bleeding/contraception/surgical history: write your note and one question.
- Relevant personal and family history: write your note and one question.
- Option and expected benefit: write your note and one question.
- Side effects and earlier-contact plan: write your note and one question.
- Review date and responsible clinician: write your note and one question.
Never delay urgent care to finish a diary or worksheet. Keep only the details you are comfortable recording.
Frequently asked questions
Does the warning change mean hormone therapy has no risks?
No. Product-specific labeling, personal history and the benefit–risk discussion still matter.
Are vaginal and systemic hormone treatments the same?
No. They have different purposes and exposure; ask which symptom the proposed option targets.
Should bleeding after menopause be ignored if it is light?
No. Arrange assessment even when it happens only once.
Sources and editorial method
Prepared for FitnessLifeMag by Biraj Kh., Founder & Editor. This is an AI-assisted editorial synthesis of selected public guidance, with targeted source checks on November 16, 2026. It has no independent clinician review and is not a systematic review or personalized medical advice.
We distinguish screening from symptom assessment, laboratory markers from health outcomes, and ingredient research from finished-product evidence. The source notes describe material access limits and recommendation dates. We did not inspect every underlying study or independently test products.
- NICHD: Menopause. Public overview of transition and symptoms.
- Office on Women’s Health: Hormone Therapy Safety. October 2026 update; benefits, risks and warning changes inspected.
- Office on Women’s Health: Menopause and Sexuality. Current public information on dryness, sexual comfort and treatment choices.
- FDA: Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026 regulatory announcement; changes apply to the identified products, not a claim that all risks disappeared.
- NCCIH: Menopausal Symptoms—In Depth. Evidence and safety overview for complementary approaches; formulation differences matter.
- NHS: Postmenopausal Bleeding. Public guidance reviewed September 2026; UK referral timelines are not presented as US guarantees.